Orally Disintegrating Tablet Market

An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.

Orally Disintegrating Tablet Market contains market size and forecasts of Orally Disintegrating Tablet in global, including the following market information:

Global Orally Disintegrating Tablet Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Orally Disintegrating Tablet Market Sales, 2017-2022, 2023-2028, (M Units)

Global top five Orally Disintegrating Tablet companies in 2021 (%)

The global Orally Disintegrating Tablet market was valued at 14290 million in 2021 and is projected to reach US$ 30040 million by 2028, at a CAGR of 11.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Anti-Psychotics Drug Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Orally Disintegrating Tablet include Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company and AstraZeneca, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Orally Disintegrating Tablet manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Orally Disintegrating Tablet Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Orally Disintegrating Tablet Market Segment Percentages, by Type, 2021 (%)

Anti-Psychotics Drug

Anti-Epileptics Drug

Others

Global Orally Disintegrating Tablet Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Orally Disintegrating Tablet Market Segment Percentages, by Application, 2021 (%)

CNS Diseases

Gastrointestinal Diseases

CVS Diseases

Others

Global Orally Disintegrating Tablet Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Orally Disintegrating Tablet Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Orally Disintegrating Tablet revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Orally Disintegrating Tablet revenues share in global market, 2021 (%)

Key companies Orally Disintegrating Tablet sales in global market, 2017-2022 (Estimated), (M Units)

Key companies Orally Disintegrating Tablet sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Teva

Merck

Mylan

Pfizer

Johnson and Johnson

GSK

Otsuka

Eli Lilly and Company

AstraZeneca

Bristol-Myers Squibb

Conquer